Trial of RNActive®-Derived Cancer Vaccine and Local Radiation in in Stage IV Non Small Cell Lung Cancer (NSCLC)

Phase 1

Terminated

• Conditions: Non-Small Cell Lung Carcinoma
• Interventions: Biological: CV9202; Radiation: local radiation

• Registration Number: NCT01915524
• Lead Sponsor: CureVac

Brief Summary

The purpose of this study is to determine whether the new RNActive derived lung cancer vaccine CV9202 in combination with local radiation therapy is safe, tolerable and immunogenic for the consolidation and maintenance treatment of stage IV non small cell lung cancer (NSCLC) after first-line chemotherapy or therapy with an EGFR tyrosine kinase inhibitor.

Detailed Description

The Phase Ib study is the first clinical study with the new lung cancer vaccine CV9202. The vaccine is composed of 6 RNActive compounts, each encoding for a different antigen which is overexpressed in NSCLC compared to healthy tissue.

In order to enhance the immunogenic effect of the cancer vaccine, the study treatment will include local radiation (4 x 5 Gy), which is a well-established palliative radiation regimen that can be safely applied to metastatic lesions in the lung, bone, and soft tissue, and is well tolerated.

Patients will be enrolled into 3 strata based on histologic and molecular subtypes as follows:

Stratum 1: Patients with metastatic stage IV NSCLC and non-squamous histology, without activating epidermal growth factor receptor (EGFR) mutations, who have achieved partial response (PR) or stable disease (SD) after at least 4 cycles of platinum- and pemetrexed-based first-line chemotherapy, and an indication for maintenance therapy with pemetrexed.

Stratum 2: Patients with stage IV NSCLC and squamous cell histology, who achieved PR or SD after at least 4 cycles of platinum-based and non-platinum compound first-line chemotherapy.

Stratum 3: Patients with stage IV NSCLC and non-squamous histology, harboring an activating EGFR mutation, who have achieved PR after up to 6 months or SD after 3 - 6 months of treatment with an EGFR TKI.

In each patient, the vaccine will be administered until progression and the need to start a subsequent systemic second-line treatment, or occurrence of unacceptable toxicity requiring treatment discontinuation, whichever comes first.

Study Timeline

• Study Start: 2013-04
• Study First Submitted: 2013-07-18
• Study First Submitted QC: 2013-08-01
• Study First Posted: 2013-08-05
• Primary Completion: 2016-07
• Study Completion: 2016-07
• Status Verified: 2016-08
• Last Update Submitted: 2016-08-04
• Last Update Posted: 2016-08-05

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 26

Inclusion Criteria

1. Patients >= 18 years of age with histologically or cytologically-confirmed stage IV NSCLC, and a confirmed EGFR mutation status in case of non-squamous cell histology

   • Stratum 1: Non-squamous NSCLC without activating EGFR mutation
   • Stratum 2: Squamous NSCLC
   • Stratum 3: Non-squamous NSCLC harboring an activating EGFR mutation

2. PR or SD according to RECIST Version 1.1 after first-line therapy which should have consisted of:

   • Stratum 1: PR or SD after cisplatin or carboplatin and pemetrexed treatment (at least 4 cycles)
   • Stratum 2: PR or SD after cisplatin or carboplatin and a non-platinum compound treatment (at least 4 cycles)
   • Stratum 3: PR after up to 6 months or SD after at least 3 and up to 6 months of gefitinib or erlotinib treatment

3. For patients in stratum 1, maintenance therapy with pemetrexed should be indicated as to the investigator's opinion

4. Presence of at least one tumor lesion that is eligible for radiation with 4 x 5 GY, and at least one additional measurable tumor lesion according to RECIST Version 1.1.

   Tumor lesions eligible for radiation are:

   • Bone metastases
   • Lymph nodes in the paraclavicular, axillary or cervical regions
   • Skin or subcutaneous metastases
   • For patients in strata 1 and 2 only: Thoracic lesions (centrally located lung tumor, lymph nodes in the lung hilus or mediastinum)

5. Performance Status: Eastern Cooperative Oncology Group (ECOG) 0 to 1

Key

Read More

Exclusion Criteria

1. Previous active immunotherapy for NSCLC (including vaccination, therapy with anti-CTLA4 antibodies)

2. Estimated life expectancy ≤ 3 months

3. Need for immunosuppressive treatment including daily systemic steroid doses of ≥ 10 mg prednisone equivalent per day

4. Active skin disease (e.g. atopic dermatitis) in the areas for vaccine injection (upper arms or thighs) not allowing intradermal injections into areas of healthy skin

5. Concurrent or planned major surgery

6. Prior splenectomy or prior allogeneic bone marrow transplantation

7. History of pneumonitis

8. Documented history or active autoimmune disorders with the exception of vitiligo, diabetes mellitus type 1 or autoimmune thyroiditis requiring hormone replacement only

9. Primary or secondary immune deficiency

10. Allergies to any components of the study drug including allergy to protamine hydrochloride (e.g. allergy to protamine-containing insulin) or fish allergy

11. Seropositive for HIV, HBV, HCV or any other infection requiring anti-infection therapy

12. For patients in stratum 3: persisting >= grade 3 skin rash at time of enrollment

13. Known brain metastases with the exception of stable metastases being treated with stereotactic radiation or surgery)

    **Local German Amendment: 13. Brain metastases (symptomatic or asymptomatic) or leptomeningeal involvement

14. Uncontrolled medical condition considered as high risk for the treatment with an investigational drug (e.g. unstable diabetes mellitus, vena-cava-syndrome, uncontrolled pleural effusion, pericardial effusion, symptomatic congestive heart failure (New York Heart Association 3 or 4), unstable angina pectoris/myocardial infarction within the previous 6 months, significant cardiac arrhythmia, history of stroke or transient ischemic attack within the previous 6 months, severe hypertension according to WHO criteria, and uncontrolled systolic blood pressure ≥ 180 mmHg at the time of enrollment

15. For patients planned to undergo radiation of thoracic lesions: inadequate lung function dependent on the intended tumor volume and location to be irradiated (to be assessed by the radio oncologist)

16. History of encephalitis or multiple sclerosis

17. Active inflammatory conditions such as inflammatory bowel disease

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
CV9202 and local radiation	local radiation	CV9202 consisting of 6 RNActive-derived molecules coding for 6 different NSCLC associated antigens. local radiation (4x5 Gy)
CV9202 and local radiation	CV9202	CV9202 consisting of 6 RNActive-derived molecules coding for 6 different NSCLC associated antigens. local radiation (4x5 Gy)

Primary Outcome Measures

Name	Time	Method
Number of participants with treatment related >= grade 3 adverse events (AEs).	up to 40 months	Events are graded by the investigator using the NCI CTCAE Scale (version 4.0) which provides a grading scale for each AE term. Grade 3 = Severe Grade 4 = Life-threatening or disabling; Interim safety evaluations will be performed: * After treatment and observation of the first 6 patients until Day 43 in a given stratum.; - If \>= 2 out of 6 patients experience treatment-related \>= grade 3 AEs, enrollment in that stratum will be suspended.; * After the first 6 patients (enrolled in stratum 1 or 2) have received radiation of thoracic lesions and have been monitored for toxicity until Day 57: * If \>= 2 out of 6 patients experience \>= grade 3 radiation pneumonitis, radiation of thoracic lesions will be suspended for further patients.; * For strata 1 and 2, CV9202 administration and radiation of thoracic lesions will be considered safe for further evaluation if ≤ 20% of patients experience a \>= grade 3 radiation pneumonitis and no patients experience grade 4 radiation pneumonitis.

Secondary Outcome Measures

Name	Time	Method
progression free survival (PFS) and time to start of second-line treatment	every 6 weeks up to 18 months after start of treatment of the last patient enrolled
overall survival (OS) from time of first vaccination.	From first study treatment until time of death assessed up to 40 months
humoral and cellular immune responses against the 6 antigens encoded by CV9202.	assessments at baseline, Day 19, Day 61 after start of study treatment
overall tumor response.	At Screening and every 6 weeks during study treatment until progression up to 18 months after start of treatment of the last patient enrolled
response to second-line cancer treatment	every 3 months after completion of study treatment until death, withdrawal of informed consent, or loss to follow-up or until up to 18 months after start of treatment of the last patient enrolled
broadening of humoral immune responses (antigen spreading, i.e. change in serum antibody patterns) against a panel of tumor antigens not covered by the vaccine.	Assessment at baseline, Day 19, Day 61 and 12 weeks, 24 weeks and 48 weeks after Day 57

Trial Locations

Locations (13)

Klinikum Esslingen GmbH; 🇩🇪 Esslingen, Germany

Thoraxklinik-Heidelberg gGmbH; 🇩🇪 Heidelberg, Germany

Kantonspital St. Gallen; 🇨🇭 St. Gallen, Switzerland

Kantonsspital Graubünden; 🇨🇭 Chur, Switzerland

Innsbruck Medical University, Department of Internal Medicine V (Hematology and Oncology); 🇦🇹 Innsbruck, Austria

Kantonspital Winterthur, Oncology; 🇨🇭 Winterthur, Switzerland

University Hospital Basel, Clinic for Oncology; 🇨🇭 Basel, Switzerland

HELIOS Klinikum Emil von Behring GmbH; 🇩🇪 Berlin, Germany

University Hospital Frankfurt, Department of Medicine II: Hematology/Oncology; 🇩🇪 Frankfurt, Germany

Augusta-Kranken-Anstalt gGmbH; 🇩🇪 Bochum, Germany

Kliniken der Stadt Köln gGmbH; 🇩🇪 Cologne, Germany

University Medical Center Mainz, III. Medical Clinic and Policlinic; 🇩🇪 Mainz, Germany

Pius-Hospital Oldenburg; 🇩🇪 Oldenburg, Germany